Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Docetaxel and Cisplatin in First Line Treatment of Patients with Unknown Primary Cancer: A Multicenter Study of the Anatolian Society of Medical Oncology

  • Published : 2014.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The overall prognosis for cancers of unknown primary (CUP) is poor, median overall survival (OS) being 6-12 months. We evaluated our multicentric retrospective experience for CUP administered docetaxel and cisplatin combination therapy. Materials and Methods: A total of 29 patients that were pathologically confirmed subtypes of CUP were included in the study. The combination of docetaxel ($75mg/m^2$, day 1) and cisplatin ($75mg/m^2$, day 1) was performed as a first line regimen every 21 days. Results: The median age was 51 (range: 27-68). Some 17 patients had multimetastatic disease on the inital diagnosis. Histopathological diagnoses were well-moderate differentiated adenocarcinoma (51.7%), undifferentiated carcinoma (27.6%), squamous cell cancer (13.8%), mucoepidermoid carcinoma (3.4%) and neuroendocrine differentiated carcinoma (3.4%). Median number of cycles was 3 (range: 1-6). Objective response rate was 37.9% and clinical benefit was 58.6%. Median progression free survival (PFS) and overall survival (OS) were 6 months (range: 4.3-7.7 months) and 16 months (range: 8.1-30.9 months), respectively. Fourteen patients (60.8%) were treated in a second line setting. There was no treatment related death. Most common toxicities were nausia-vomiting (44.6%) and fatigue (34.7%), serious cases (grade 3/4) suffering nausia-vomiting (10.3%), neutropenia (13.8%) and febrile neutropenia (n=1). Conclusion: The combination of cisplatin and docetaxel is an effective regimen for selected patients with CUP.

Keywords

References

  1. Adenis A, Ferte C, Penel N (2010). Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis. Invest New Drugs. 28, 178-84. https://doi.org/10.1007/s10637-009-9261-5
  2. Briasoulis E, Kalofonos H, Bafaloukos D, et al (2000). Carboplatin plus paclitaxel in unknown primary carcinoma: A Phase II Hellenic Cooperative Oncology Group study. J Clin Oncol 18, 3101-7. https://doi.org/10.1200/JCO.2000.18.17.3101
  3. Culine S, Kramar A, Saghatchian M, et al (2002). Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 20, 4679-83. https://doi.org/10.1200/JCO.2002.04.019
  4. Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  5. Fernandez-Cotarelo MJ, Guerra-Vales JM, Colina F, de la Cruz J (2010). Prognostic factors in cancer of unknown primary site.Tumori. 96, 111-6. https://doi.org/10.1177/030089161009600118
  6. Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G (2011); ESMO Guidelines Working Group. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 22, 64-8.
  7. Goldberg RM, Smith FP, Ueno W, Ahlgren JD, Schein PS (1986). 5-Fluorouracil, adriamycin, mitomycin in the treatment of adenocarcinoma of unknown primary. J Clin Oncol, 4, 395-9. https://doi.org/10.1200/JCO.1986.4.3.395
  8. Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, Ioannidis JP, Pavlidis N (2009). Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple treatments meta-analysis. Cancer Treat Rev, 35, 570-3. https://doi.org/10.1016/j.ctrv.2009.05.005
  9. Greco FA, Burris 3rd, Erland JB, et al (2000). Carcinoma of unknown primary site. Cancer, 89, 2655-60. https://doi.org/10.1002/1097-0142(20001215)89:12<2655::AID-CNCR19>3.0.CO;2-9
  10. Greco FA, Erland JB, Morrissey LH, et al (2000). Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol, 11, 211-5. https://doi.org/10.1023/A:1008369812295
  11. Greco FA, Gray J, Burris HA 3rd, Erland JB, Morrissey LH, Hainsworth JD (2001). Taxane based chemotherapy for patients with carcinoma of unknown primary site. Cancer J, 7, 203-12.
  12. Greco FA, Oien K, Erlander M, et al (2012). Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol, 23, 98-304 https://doi.org/10.1093/annonc/mdr064
  13. Hainsworth JD, Spigel DR, Clark BL, et al (2010). Paclitaxel/ carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J, 16, 70-5. https://doi.org/10.1097/PPO.0b013e3181c6aa89
  14. Lazaridis G, Pentheroudakis G, Fountzilas G, Pavlidis N (2008). Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Cancer Treat Rev, 34, 693-700. https://doi.org/10.1016/j.ctrv.2008.05.005
  15. Massard C, Loriot Y, Fizazi K (2011). Carcinomas of an unknown primary origin-diagnosis and treatment. Nat Rev Clin Oncol. 8, 701-10. https://doi.org/10.1038/nrclinonc.2011.158
  16. Mukai H, Katsumata N, Ando M, Watanabe T (2010). Safety and efficacy of a combination of docetaxel and cisplatin in patients with unknown primary cancer. Am J Clin Oncol, 33, 32-5. https://doi.org/10.1097/COC.0b013e31819ccc55
  17. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. 2009.
  18. Nishimori H, Takahashi S, Kiura K, et al (2010). Cancer of unknown primary site: a review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a single institute in Japan. Acta Med Okayama. 64, 285-91.
  19. Pavlidis N, Pentheroudakis G (2012). Cancer of unknown primary site. Lancet, 379, 1428-35. https://doi.org/10.1016/S0140-6736(11)61178-1
  20. Hemminki K, Bevier M, Hemminki A, Sundquist J (2012). Survival in cancer of unknown primary site: populationbased analysis by site and histology. Ann Oncol, 23, 1854-63 https://doi.org/10.1093/annonc/mdr536
  21. Pouessel D, Culine S, Becht C, et al (2004). Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer, 100, 1257-61. https://doi.org/10.1002/cncr.20100
  22. Seve P, Ray-Coquard I, Trillet-Lenoir V, et al (2006). Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer. 107, 2698-705. https://doi.org/10.1002/cncr.22300
  23. Yakushiji S, Ando M, Yonemori K, et al (2006). Cancer of unknown primary site: Review of consecutive cases at the national cancer center hospital of japan. Int J Clin Oncol 11, 421-5. https://doi.org/10.1007/s10147-006-0599-9

Cited by

  1. Neuroendocrine tumors in the Iran Cancer Institute: Predictive Factors of Patient Survival vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7835
  2. Anti-cancer Properties of a Sesquiterpene Lactone-bearing Fraction from Artemisia khorassanica vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.863
  3. A Simple Risk Model to Predict Survival in Patients With Carcinoma of Unknown Primary Origin vol.94, pp.47, 2015, https://doi.org/10.1097/MD.0000000000002135